{"id":"lid104","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the serotonin receptor, which leads to a decrease in serotonin levels in the brain. This decrease in serotonin levels is thought to be beneficial for patients with depression.","oneSentence":"LID104 is a small molecule that targets the serotonin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:58.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT05886088","phase":"PHASE3","title":"Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"EMS","startDate":"2024-02","conditions":"Type 2 Diabetes Mellitus","enrollment":597}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LID104","genericName":"LID104","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LID104 is a small molecule that targets the serotonin receptor. Used for Major depressive disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}